keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous adverse effects, drug

keyword
https://www.readbyqxmd.com/read/28801835/fabrication-of-acyclovir-loaded-flexible-membrane-vesicles-fmvs-evidence-of-preclinical-efficacy-of-antiviral-activity-in-murine-model-of-cutaneous-hsv-1-infection
#1
Gajanand Sharma, Kanika Thakur, Arvind Setia, Basant Amarji, Mini P Singh, Kaisar Raza, Om Prakash Katare
The present investigation focuses on the development and evaluation of acyclovir-loaded flexible membrane vesicles (ACY-FMVs) and evaluates their targeting potential to localize the drug into skin layers. The drug-loaded FMVs were prepared by thin-film hydration method and characterized for various attributes including micromeritics, entrapment efficiency, vesicle shape, size, and degree of deformability. The values of particle size and zeta potential of the developed carrier system were found to be 453.7 nm and - 11...
August 11, 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/28750665/renal-damage-induced-by-pemetrexed-causing-drug-discontinuation-a-case-report-and-review-of-the-literature
#2
Yassir Sbitti, Hafsa Chahdi, Khaoula Slimani, Adil Debbagh, Anouar Mokhlis, Abderrahmane Albouzidi, Fahd Bennani, Hassan Errihani, Mohamed Ichou
BACKGROUND: Pemetrexed maintenance therapy holds tremendous potential in improving the survival of patients with advanced pulmonary adenocarcinoma. Major side effects include myelosuppression and cutaneous reactions. However, little data are available on pemetrexed nephrotoxicity. Our case describes clinically relevant renal events leading to treatment discontinuation in routine practice. CASE PRESENTATION: We report a case of a 69-year-old Moroccan man treated for metastatic non-small cell lung cancer...
July 28, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28735040/co-encapsulation-of-paclitaxel-and-c6-ceramide-in-tributyrin-containing-nanocarriers-improve-co-localization-in-the-skin-and-potentiate-cytotoxic-effects-in-2d-and-3d-models
#3
Vanessa F M Carvalho, Amanda Migotto, Daniela V Giacone, Débora P de Lemos, Thalita B Zanoni, Silvya S Maria-Engler, Leticia V Costa-Lotufo, Luciana B Lopes
Considering that tumor development is generally multifactorial, therapy with a combination of agents capable of potentiating cytotoxic effects is promising. In this study, we co-encapsulated C6 ceramide (0.35%) and paclitaxel (0.50%) in micro and nanoemulsions containing tributyrin (a butyric acid pro-drug included for potentiation of cytotoxicity), and compared their ability to co-localize the drugs in viable skin layers. The nanoemulsion delivered 2- and 2.4-fold more paclitaxel into viable skin layers of porcine skin in vitro at 4 and 8h post-application than the microemulsion, and 1...
July 19, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28718873/clinical-features-of-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-syndrome-a-study-of-25-patients-in-korea
#4
Jin Y Lee, Suh-Young Lee, Ji E Hahm, Jae W Ha, Chul W Kim, Sang S Kim
BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare adverse drug reaction. This study aimed to evaluate the incidence of association with individual drugs, clinical manifestations, disease course, and outcomes of DRESS. METHODS: Using the criteria of the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR), the medical records of 25 patients diagnosed with DRESS between 2006 and 2015 were retrospectively reviewed...
July 18, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28707278/daclizumab-development-clinical-trials-and-practical-aspects-of-use-in-multiple-sclerosis
#5
REVIEW
Laura E Baldassari, John W Rose
Daclizumab is a humanized monoclonal antibody directed towards CD25, the alpha subunit of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple mechanisms, including reduction of IL-2-mediated lymphocyte activation and upregulation of CD56-bright natural killer cells. Intravenous daclizumab (Zenapax™) was initially approved for prevention of rejection in renal transplant. In subsequent early testing, followed by larger-scale phase II and phase III trials, both intravenous and subcutaneous daclizumab have demonstrated clinical efficacy in the treatment of multiple sclerosis...
July 13, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28686776/adapalene-benzoyl-peroxide-gel-0-3-2-5-effective-acne-therapy-regardless-of-age-or-gender
#6
Linda Stein Gold, William P Werschler, Jennifer Mohawk
<p>BACKGROUND: Acne vulgaris affects a diverse group of people, and there is an increasingly wide variety of acne treatments. Because of the many options, clinicians have a better ability to individualize treatment; however, achieving optimal results relies on understanding how various agents perform in specific population segments. Fixed-combination adapalene plus benzoyl peroxide (A/BPO) is a first-line recommended acne therapy and is available in two adapalene concentrations (0.1% and 0.3%) combined with BPO 2...
June 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28669525/mechanisms-of-skin-toxicity-associated-with-metabotropic-glutamate-receptor-5-negative-allosteric-modulators
#7
Falgun Shah, Antonia F Stepan, Alison O'Mahony, Sharlene Velichko, Alexandra E Folias, Christopher Houle, Christopher L Shaffer, John Marcek, Jessica Whritenour, Robert Stanton, Ellen L Berg
Cutaneous reactions represent one of the most common adverse drug effects observed in clinical trials leading to substantial compound attrition. Three negative allosteric modulators (NAMs) of metabotropic glutamate receptors (mGluRs), which represent an important target for neurological diseases, developed by Pfizer, were recently failed in preclinical development due to delayed type IV skin hypersensitivity observed in non-human primates (NHPs). Here we employed large-scale phenotypic profiling in standardized panels of human primary cell/co-culture systems to characterize the skin toxicity mechanism(s) of mGluR5 NAMs from two different series...
July 20, 2017: Cell Chemical Biology
https://www.readbyqxmd.com/read/28623363/machine-learning-workflow-to-enhance-predictions-of-adverse-drug-reactions-adrs-through-drug-gene-interactions-application-to-drugs-for-cutaneous-diseases
#8
Kalpana Raja, Matthew Patrick, James T Elder, Lam C Tsoi
Adverse drug reactions (ADRs) pose critical public health issues, affecting over 6% of hospitalized patients. While knowledge of potential drug-drug interactions (DDI) is necessary to prevent ADR, the rapid pace of drug discovery makes it challenging to maintain a strong insight into DDIs. In this study, we present a novel literature-mining framework for enhancing the predictions of DDIs and ADR types by integrating drug-gene interactions (DGIs). The ADR types were adapted from a DDI corpus, including i) adverse effect; ii) effect at molecular level; iii) effect related to pharmacokinetics; and iv) DDIs without known ADRs...
June 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28594314/tailoring-of-recommendations-to-reduce-serious-cutaneous-adverse-drug-reactions-a-pharmacogenomics-approach
#9
Wei Chuen Tan-Koi, Cynthia Sung, Yong Yeow Chong, Aisha Lateef, Shiu Ming Pang, Archana Vasudevan, Derrick Aw, Nai Lee Lui, Shan Xian Lee, Ee Chee Ren, Evelyn Sc Koay, Yong Kwang Tay, Yen Loo Lim, Haur Yueh Lee, Di Dong, Celine Loke, Liesbet Tan, Michael Limenta, Edmund Jd Lee, Dorothy Toh, Cheng Leng Chan
The Health Sciences Authority launched a pharmacogenetics initiative in 2008 to facilitate evaluation of pharmacogenetics associations pertinent for Chinese, Malays and Indians in Singapore. The aim was to reduce the incidence and unpredictability of serious adverse drug reactions, with a focus on serious skin adverse drug reactions. This paper describes the gathering of evidence and weighing of factors that led to different genotyping recommendations for HLA-B*15:02 with carbamazepine and HLA-B*58:01 with allopurinol, despite both having strong genetic associations...
June 8, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28594280/rapid-and-reliable-screening-of-hla-b-15-02-in-four-chinese-populations-using-single-tube-multiplex-real-time-pcr-assay
#10
Huijuan Wang, Xing Kang, Shaohe Zhou, Rong Chen, Zhengbin Liu, Min Han, Chao Chen, Yongkuan Gong
AIM:  HLA-B*15:02 screening should be performed to prevent antiepileptic drug induced severe cutaneous adverse reactions in populations of Asian origin. This study aimed to develop fast and reliable HLA-B*15:02 genotyping method and to investigate the distribution of HLA-B*15:02 in different Chinese ethnicities. MATERIALS & METHODS: A single-tube multiplex real-time PCR assay for HLA-B*15:02 genotyping was established by combining allele-specific primers with TaqMan probes...
June 8, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28558061/low-versus-high-dose-of-antimony-for-american-cutaneous-leishmaniasis-a-randomized-controlled-blind-non-inferiority-trial-in-rio-de-janeiro-brazil
#11
Mauricio Naoto Saheki, Marcelo Rosandiski Lyra, Sandro Javier Bedoya-Pacheco, Liliane de Fátima Antônio, Maria Inês Fernandes Pimentel, Mariza de Matos Salgueiro, Érica de Camargo Ferreira E Vasconcellos, Sonia Regina Lambert Passos, Ginelza Peres Lima Dos Santos, Madelon Novato Ribeiro, Aline Fagundes, Maria de Fátima Madeira, Eliame Mouta-Confort, Mauro Célio de Almeida Marzochi, Cláudia Maria Valete-Rosalino, Armando de Oliveira Schubach
BACKGROUND: Although high dose of antimony is the mainstay for treatment of American cutaneous leishmaniasis (ACL), ongoing major concerns remain over its toxicity. Whether or not low dose antimony regimens provide non-inferior effectiveness and lower toxicity has long been a question of dispute. METHODS: A single-blind, non-inferiority, randomized controlled trial was conducted comparing high dose with low dose of antimony in subjects with ACL treated at a referral center in Rio de Janeiro, an endemic area of Leishmania (Viannia) braziliensis transmission...
2017: PloS One
https://www.readbyqxmd.com/read/28539982/misuse-of-topical-corticosteroids-on-facial-skin-a-study-of-200-patients
#12
Rohini Sharma, Sameer Abrol, Mashqoor Wani
BACKGROUND: Topical corticosteroids have become available as over the counter drugs and are widely misused for various conditions. OBJECTIVE: The aim of this study is to assess the clinical and epidemiological aspects of the unjustified use of topical corticosteroids for facial skin. METHODS: A total of 200 patients with facial dermatoses and topical corticosteroid misapplication daily over face for not less than 30 days were included in the study...
March 31, 2017: Journal of Dermatological Case Reports
https://www.readbyqxmd.com/read/28476075/drugs-for-discoid-lupus-erythematosus
#13
REVIEW
Sue Jessop, David A Whitelaw, Matthew J Grainge, Prativa Jayasekera
BACKGROUND: Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most appropriate treatment for an individual with DLE...
May 5, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28460833/application-of-nanotechnology-in-treatment-of-leishmaniasis-a-review
#14
REVIEW
Maryam Akbari, Ahmad Oryan, Gholamreza Hatam
Leishmaniasis is a neglected tropical disease caused by a protozoan species of the genus Leishmania affecting mostly the developing countries. The disease with current mortality rate of 50,000 deaths per year threatens approximately 350 million people in more than 90 countries all over the world. Cutaneous, mucocutaneous and visceral leishmaniasis are the most frequent forms of the disease. Chemotherapy still relies on the use of pentavalent antimonials, amphotericin B, liposomal amphotericin B and miltefosin...
April 28, 2017: Acta Tropica
https://www.readbyqxmd.com/read/28447489/forodesine-in-the-treatment-of-cutaneous-t-cell-lymphoma
#15
REVIEW
Daniel J Lewis, Madeleine Duvic
Cutaneous T-cell lymphoma (CTCL) is characterized by the accumulation of neoplastic CD4+ T lymphocytes in the skin. Given the lack of curative treatments for CTCL, there is a significant need for new, superior therapies. Forodesine is a transition-state analogue that inhibits purine nucleoside phosphorylase. Because it selectively targets T lymphocytes, it represents a drug of interest for the treatment of CTCL. Areas covered: Phase I/II dose-ranging studies of intravenous (IV) and oral forodesine demonstrated its activity, safety, and tolerability for refractory CTCL...
June 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28442875/extreme-phenotype-of-epidermal-growth-factor-receptor-inhibitor-induced-destructive-folliculitis
#16
Florian Anzengruber, Barbara Meier, Julia-Tatjana Maul, Katrin Kerl, Lars E French, Alexander A Navarini
Due to the increasingly widespread use and side effect profile of epidermal growth factor receptor inhibitors (EGFRIs), cutaneous side effects of these drugs are frequently encountered. The EGFR is expressed on keratinocytes and fibroblasts. Inhibition of EGFR can produce a range of cutaneous adverse effects, the most frequent being a characteristic acneiform skin eruption. As the latter is associated with good anti-neoplastic responses, the onset of EGFRI-induced acneiform skin eruption is typically viewed as a positive sign by patients and physicians...
October 2016: International Journal of Trichology
https://www.readbyqxmd.com/read/28441954/electrochemotherapy-efficacy-evaluation-for-treatment-of-locally-advanced-stage-iii-cutaneous-squamous-cell-carcinoma-a-22-cases-retrospective-analysis
#17
Gianluca Di Monta, Corrado Caracò, Ester Simeone, Antonio Maria Grimaldi, Ugo Marone, Massimiliano Di Marzo, Vito Vanella, Lucia Festino, Marco Palla, Stefano Mori, Nicola Mozzillo, Paolo Antonio Ascierto
BACKGROUND: Extensive squamous cell carcinoma has few therapeutic options. In such cases, electrochemotherapy involving electroporation combined with antineoplastic drug appears to be a new potential option and may be considered as an alternative treatment. The aim of this retrospective single-center study was to evaluate electrochemotherapy efficacy in treatment of locally advanced stage III squamous cell carcinoma, in which surgical procedures would have entailed wide tissue sacrifice...
April 26, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28436279/treatment-of-painful-radiculopathies-with-capsaicin-8-cutaneous-patch
#18
R Baron, R D Treede, F Birklein, T Cegla, R Freynhagen, M L Heskamp, K U Kern, C Maier, R Rolke, S Seddigh, C Sommer, S Ständer, C Maihöfner
BACKGROUND AND OBJECTIVE: The treatment of neuropathic pain due to low-back (lumbosacral) radiculopathies, a common source of neuropathic pain, is challenging and often requires a multimodal therapeutic approach. The capsaicin 8% patch is the first topical analgesic licensed for peripheral neuropathic pain. To evaluate this treatment, a subset of patients with painful radiculopathy (lumbar and cervical, including ventral and dorsal rami) enrolled into the multicenter, non-interventional QUEPP study (Qutenza (2) - safety and effectiveness in peripheral neuropathic pain) was analyzed...
May 4, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28422003/efficacy-and-safety-of-leflunomide-as-an-adjuvant-drug-in-refractory-dermatomyositis-with-primarily-cutaneous-activity
#19
Renata C de Souza, Fernando H C de Souza, Renata Miossi, Samuel K Shinjo
OBJECTIVES: To evaluate leflunomide as an adjuvant drug in refractory dermatomyositis (DM) with primarily cutaneous activity. METHODS: A retrospective, single-centre, cohort study including 18 adult patients with DM (classical or clinically amyopathic DM) and cutaneous activity from 2001 to 2016 was conducted. Patients were dependent on glucocorticoid and refractory to at least two full-dose immunosuppressants/immunomodulators or presented previous adverse events with immunobiological drugs...
April 18, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28413391/minocycline-induced-hyperpigmentation-in-a-patient-treated-with-erlotinib-for-non-small-cell-lung-adenocarcinoma
#20
Ann T Bell, John W Roman, Max L Gratrix, Christina E Brzezniak
INTRODUCTION: While epidermal growth factor receptor (EGFR) inhibitors have improved progression-free survival in patients with non-small cell lung cancer (NSCLC), one of the most common adverse effects is papulopustular skin eruption, which is frequently severe enough to be treated with oral minocycline or doxycycline. CASE: We present a case of an 87-year-old man who developed a severe papulopustular skin eruption secondary to erlotinib therapy for NSCLC. Control of the eruption with 100 mg of minocycline twice daily for 8 months eventually led to blue-gray skin hyperpigmentation...
January 2017: Case Reports in Oncology
keyword
keyword
109299
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"